A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
← catalyst calendarNCT05836324 · readout in 988 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
570estimated
Sites
39
Countries
China, Denmark, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-24 | actual | When the study began enrolling |
| Primary completion | 2029-05-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-03 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
- Drug: INCA33890
- Drug: bevacizumab
- Drug: FOLFIRI
- Drug: FOLFOX
- Drug: Cetuximab
- Drug: ADG126
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicities (DLTs)
measured Up to 28 days
Treatment Emerging Adverse Events (TEAEs)
measured Up to 2 years
TEAEs leading to dose modification or discontinuation
measured Up to 2 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed